SUPR-3D: A randomized phase iii trial comparing simple unplanned palliative radiotherapy versus 3d conformal radiotherapy for patients with bone metastases: study protocol

Autor: Tanya Berrang, Marco Arimare, Lindsay Mathews, Quinn Matthews, Roel Schlijper, Benjamin Mou, Nick Chng, Alexander V. Louie, Devin Schellenberg, David A. Palma, Joanna Laba, Boris Valev, Robert Olson, Fred Hsu, Shilo Lefresne
Jazyk: angličtina
Rok vydání: 2019
Předmět:
Adult
Male
Quality of life
Cancer Research
medicine.medical_specialty
Adolescent
Nausea
Vomiting
medicine.medical_treatment
Bone Neoplasms
lcsh:RC254-282
030218 nuclear medicine & medical imaging
Radiation-induced nausea and vomiting
03 medical and health sciences
Young Adult
Study Protocol
0302 clinical medicine
Palliative radiotherapy
Surgical oncology
3d conformal radiotherapy
Genetics
medicine
Humans
Aged
Aged
80 and over
Radiotherapy
business.industry
Radiotherapy Planning
Computer-Assisted
Bone metastases
Palliative Care
Radiotherapy Dosage
Middle Aged
lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens
Volumetric modulated arc therapy
Radiation therapy
Treatment Outcome
Oncology
030220 oncology & carcinogenesis
Female
Radiology
Radiotherapy
Intensity-Modulated
medicine.symptom
business
Follow-Up Studies
Zdroj: BMC Cancer
BMC Cancer, Vol 19, Iss 1, Pp 1-8 (2019)
DOI: 10.14288/1.0384870
Popis: Background Bone metastases in the lower spine and pelvis are effectively palliated with radiotherapy (RT), though this can come with side effects such as radiation induced nausea and vomiting (RINV). We hypothesize that high rates of RINV occur in part because of the widespread use of inexpensive simple unplanned palliative radiotherapy (SUPR), over more complex and resource intensive 3D conformal RT, such as volumetric modulated arc therapy (VMAT). Methods This is a randomized, multi-centre phase III trial of SUPR versus VMAT. We will accrue 250 patients to assess the difference in patient-reported RINV. This study is powered to detect a difference in quality of life between patients treated with VMAT vs. SUPR. Discussion This trial will determine if VMAT reduces early toxicity compared to SUPR and may provide justification for this more resource-intensive and costly form of RT. Trial registration Clinicaltrials.gov identifier: NCT03694015. Date of registration: October 3, 2018.
Databáze: OpenAIRE
Externí odkaz: